Swedish Orphan Biovitrum AB (publ) Q2 2023 Earnings Report

Swedish Orphan Biovitrum AB (publ) EPS Results

• Actual EPS: $0.14
• Consensus EPS: $0.11
• Beat/Miss: Beat by +$0.03
• One Year Ago EPS: N/A

Swedish Orphan Biovitrum AB (publ) Revenue Results

• Actual Revenue: $463.04 million
• Expected Revenue: $397.52 million
• Beat/Miss: Beat by +$65.52 million
• YoY Revenue Growth: N/A

Swedish Orphan Biovitrum AB (publ) Announcement Details

• Quarter: Q2 2023
• Date: 7/18/2023
• Time: N/A

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Sanofi, Apellis Pharmaceuticals Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Solna, Sweden.